Exchange: NYSEMkt·Updated 04:15 PM EST

NSRX Nasus Pharma Ltd.

$2.29
$0.26
(10.20%)
Today
Closed $2.29
$0.00
(0.00%)
After Hours
Mkt Cap$29.86M
Vol33,865.00

About NSRX

Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.
47

Neutral Sentiment

How do you feel about NSRX?

Medusana
$NSRX In September 2026 Nasus announced FDA clearance to initiate a clinical study of NS002 for anaphylaxis. This is a meaningful regulatory milestone, but it is not FDA marketing approval.<<

Advertisement|Remove ads.